Amgen Inc.
Amgen Inc. AMGN Peers
See (AMGN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMGN | $290.33 | +1.13% | 156.1B | 26.47 | $10.97 | +3.19% |
| LLY | $769.97 | +0.56% | 729.7B | 62.55 | $12.31 | +0.73% |
| AZN | $72.89 | +0.74% | 451.9B | 29.39 | $2.48 | +2.11% |
| JNJ | $155.02 | +0.89% | 373B | 17.24 | $8.99 | +3.24% |
| ABBV | $189.86 | +1.27% | 335.4B | 81.14 | $2.34 | +3.36% |
| NVO | $74.64 | +2.74% | 334.8B | 20.91 | $3.57 | +2.16% |
| NVS | $117.98 | +0.16% | 233B | 18.35 | $6.43 | +3.39% |
| MRK | $78.94 | +1.69% | 198.2B | 11.47 | $6.88 | +4.00% |
| GILD | $112.46 | +1.81% | 139.9B | 14.53 | $7.74 | +2.76% |
| PFE | $23.34 | +0.95% | 132.7B | 16.91 | $1.38 | +7.27% |
Stock Comparison
AMGN vs LLY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, LLY has a market cap of 729.7B. Regarding current trading prices, AMGN is priced at $290.33, while LLY trades at $769.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas LLY's P/E ratio is 62.55. In terms of profitability, AMGN's ROE is +0.93%, compared to LLY's ROE of +0.77%. Regarding short-term risk, AMGN is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs AZN Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, AZN has a market cap of 451.9B. Regarding current trading prices, AMGN is priced at $290.33, while AZN trades at $72.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas AZN's P/E ratio is 29.39. In terms of profitability, AMGN's ROE is +0.93%, compared to AZN's ROE of +0.19%. Regarding short-term risk, AMGN is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs JNJ Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, JNJ has a market cap of 373B. Regarding current trading prices, AMGN is priced at $290.33, while JNJ trades at $155.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas JNJ's P/E ratio is 17.24. In terms of profitability, AMGN's ROE is +0.93%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, AMGN is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs ABBV Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, ABBV has a market cap of 335.4B. Regarding current trading prices, AMGN is priced at $290.33, while ABBV trades at $189.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas ABBV's P/E ratio is 81.14. In terms of profitability, AMGN's ROE is +0.93%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, AMGN is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs NVO Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, NVO has a market cap of 334.8B. Regarding current trading prices, AMGN is priced at $290.33, while NVO trades at $74.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas NVO's P/E ratio is 20.91. In terms of profitability, AMGN's ROE is +0.93%, compared to NVO's ROE of +0.81%. Regarding short-term risk, AMGN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs NVS Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, NVS has a market cap of 233B. Regarding current trading prices, AMGN is priced at $290.33, while NVS trades at $117.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas NVS's P/E ratio is 18.35. In terms of profitability, AMGN's ROE is +0.93%, compared to NVS's ROE of +0.31%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs MRK Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, MRK has a market cap of 198.2B. Regarding current trading prices, AMGN is priced at $290.33, while MRK trades at $78.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas MRK's P/E ratio is 11.47. In terms of profitability, AMGN's ROE is +0.93%, compared to MRK's ROE of +0.38%. Regarding short-term risk, AMGN is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs GILD Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, GILD has a market cap of 139.9B. Regarding current trading prices, AMGN is priced at $290.33, while GILD trades at $112.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas GILD's P/E ratio is 14.53. In terms of profitability, AMGN's ROE is +0.93%, compared to GILD's ROE of +0.32%. Regarding short-term risk, AMGN is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs PFE Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, PFE has a market cap of 132.7B. Regarding current trading prices, AMGN is priced at $290.33, while PFE trades at $23.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas PFE's P/E ratio is 16.91. In terms of profitability, AMGN's ROE is +0.93%, compared to PFE's ROE of +0.09%. Regarding short-term risk, AMGN is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs SNY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, SNY has a market cap of 123B. Regarding current trading prices, AMGN is priced at $290.33, while SNY trades at $50.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas SNY's P/E ratio is 17.72. In terms of profitability, AMGN's ROE is +0.93%, compared to SNY's ROE of +0.08%. Regarding short-term risk, AMGN is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs BMY Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, BMY has a market cap of 98.5B. Regarding current trading prices, AMGN is priced at $290.33, while BMY trades at $48.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas BMY's P/E ratio is 18.05. In terms of profitability, AMGN's ROE is +0.93%, compared to BMY's ROE of +0.32%. Regarding short-term risk, AMGN is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs CELG-RI Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, CELG-RI has a market cap of 84.2B. Regarding current trading prices, AMGN is priced at $290.33, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, AMGN is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs GSK Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, GSK has a market cap of 83.5B. Regarding current trading prices, AMGN is priced at $290.33, while GSK trades at $41.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas GSK's P/E ratio is 19.99. In terms of profitability, AMGN's ROE is +0.93%, compared to GSK's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs HZNP Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMGN is priced at $290.33, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.93%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for AMGN.
AMGN vs BIIB Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, BIIB has a market cap of 19.5B. Regarding current trading prices, AMGN is priced at $290.33, while BIIB trades at $133.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas BIIB's P/E ratio is 13.14. In terms of profitability, AMGN's ROE is +0.93%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, AMGN is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs GRFS Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, GRFS has a market cap of 7.4B. Regarding current trading prices, AMGN is priced at $290.33, while GRFS trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas GRFS's P/E ratio is 33.92. In terms of profitability, AMGN's ROE is +0.93%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, AMGN is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs OGN Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, AMGN is priced at $290.33, while OGN trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas OGN's P/E ratio is 3.32. In terms of profitability, AMGN's ROE is +0.93%, compared to OGN's ROE of +1.82%. Regarding short-term risk, AMGN is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs CTOR Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, CTOR has a market cap of 75.1M. Regarding current trading prices, AMGN is priced at $290.33, while CTOR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas CTOR's P/E ratio is -2.76. In terms of profitability, AMGN's ROE is +0.93%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, AMGN is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SCLXW Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, SCLXW has a market cap of 44.3M. Regarding current trading prices, AMGN is priced at $290.33, while SCLXW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SCLX Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, SCLX has a market cap of 43.9M. Regarding current trading prices, AMGN is priced at $290.33, while SCLX trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas SCLX's P/E ratio is -0.41. In terms of profitability, AMGN's ROE is +0.93%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs MIRA Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, MIRA has a market cap of 23.7M. Regarding current trading prices, AMGN is priced at $290.33, while MIRA trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas MIRA's P/E ratio is -2.98. In terms of profitability, AMGN's ROE is +0.93%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs SRXH Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, SRXH has a market cap of 7.5M. Regarding current trading prices, AMGN is priced at $290.33, while SRXH trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas SRXH's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.93%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, AMGN is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.
AMGN vs CRXT Comparison
AMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 156.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMGN is priced at $290.33, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 26.47, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMGN's ROE is +0.93%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMGN is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for AMGN.